Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 16 小时前评分70
正文 · 机器翻译
Erica Mayer 博士（@elmayermd）在 #ESMO26 HR+ 乳腺癌海报展示会上介绍了近期专家共识，探讨 HR+/HER2− 乳腺癌中 ribociclib 相关肝脏不良事件的管理。#BreastCancer
59 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Dana-Farber’s Breast Oncology Center · x.com